Interestingly, our analysis of large-cell neuroendocrine carcinoma (LCNEC) samples revealed that loss of PTEN and PHLDA3 often occurs in the same tumors, and these losses have an additive effect on AKT activation [5]. The gene discussed is PTEN; the disease is large cell neuroendocrine carcinoma.